Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland

References

• Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161–1170.
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–553.
   PubMed Web of Science ®Google Scholar
• Ylinen E, Salmela L, Peräsaari J, et al. Human leucocyte antigens B*08, DRB1*03 and DRB1*13 are significantly associated with autoimmune liver and biliary diseases in Finnish children. Acta Paediatr. 2016;106:322–326.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102–1111.
   PubMed Web of Science ®Google Scholar
• Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17–19.
   PubMed Web of Science ®Google Scholar
• Tenca A, Färkkilä M, Jalanko H, et al. Environmental risk factors of pediatric-onset primary sclerosing cholangitis and autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2016;62:437–442.
   PubMed Web of Science ®Google Scholar
• Deneau MR, El-Matary W, Valentino PL, et al. The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology. 2017;66:518–527.
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48:510–518.
   PubMed Web of Science ®Google Scholar
• Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–96.
   PubMed Web of Science ®Google Scholar
• Tenca A, Färkkilä M, Arola J, et al. Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. United Eur Gastroenterol J. 2016;4:562–569.
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.
   PubMed Web of Science ®Google Scholar
• Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.
   PubMed Web of Science ®Google Scholar
• Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC phenotypes of PSC-IBD. Curr Gastroenterol Rep. 2018;20:16.
   PubMedGoogle Scholar
• Ordonez F, Lacaille F, Canioni D, et al. Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? Inflamm Bowel Dis. 2012;18:1809–1817.
   PubMed Web of Science ®Google Scholar
• Lascurain L, Jensen MK, Guthery SL, et al. Inflammatory bowel disease phenotype in pediatric primary sclerosing cholangitis. Inflamm Bowel Dis. 2016;22:146–150.
   PubMed Web of Science ®Google Scholar
• Shiau H, Ihekweazu FD, Amin M, et al. Unique inflammatory bowel disease phenotype of pediatric primary sclerosing cholangitis: a single-center study. J Pediatr Gastroenterol Nutr. 2017;65:404–409.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Loftus EV, Sandborn WJ, et al. Pediatric “PSC-IBD”: a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr. 2001;33:296–300.
   PubMed Web of Science ®Google Scholar
• Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33:854–862.
   PubMed Web of Science ®Google Scholar
• Ricciuto A, Fish J, Carman N, et al. Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2018;16:1098–1105.e1.
   PubMed Web of Science ®Google Scholar
• Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–2055.
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995;22:1415–1422.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Perrault J, El YM, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003;38:210–217.
   PubMed Web of Science ®Google Scholar
• Miloh T, Arnon R, Shneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7:239–245.
   PubMed Web of Science ®Google Scholar
• Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392–1400.
   PubMed Web of Science ®Google Scholar
• Valentino PL, Wiggins S, Harney S, et al. The natural history of primary sclerosing cholangitis in children: a large single-center longitudinal cohort study. J Pediatr Gastroenterol Nutr. 2016;63:603–609.
   PubMed Web of Science ®Google Scholar
• Ward JBJ, Lajczak NK, Kelly OB, et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol Gastrointest Liver Physiol. 2017;312:G550–G558.
   PubMed Web of Science ®Google Scholar
• Singh S, Khanna S, Pardi DS, et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19:1631.
   PubMed Web of Science ®Google Scholar
• Liver EAftSot. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
   PubMed Web of Science ®Google Scholar
• Aabakken L, Karlsen TH, Albert J, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy. 2017;49:588–608.
   PubMed Web of Science ®Google Scholar
• Nieminen U, Färkkilä M. Malignancies in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:81–89.
   PubMed Web of Science ®Google Scholar
• Nieminen U, Jussila A, Nordling S, et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer. 2014;134:189–196.
   PubMed Web of Science ®Google Scholar
• Turunen P, Ashorn M, Auvinen A, et al. Long-term health outcomes in pediatric inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2009;15:56–62.
   PubMed Web of Science ®Google Scholar
• Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234–239.
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40:1379–1386.
   PubMed Web of Science ®Google Scholar